Instituto Nacional De Enfermedades Respiratorias Ismael Cosio Villegas Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2012
NCT05506865
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas" | Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas" | Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas

Active Ingredients

Drugs in Phase 4 Trials (2)

indacaterol (arcapta neohaler) (1 trial)

tiotropium (spiriva) (1 trial)

Drugs in Phase 2 Trials (2)

nitazoxanide (Alinia) (1 trial)

tofacitinib (xeljanz) (1 trial)

Drugs in Other Trials (1)

citrulline (1 trial)

Indications

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5